Universidade Estadual de Londrina

About: Universidade Estadual de Londrina is a education organization based out in Londrina, Brazil. It is known for research contribution in the topics: Population & Toxoplasma gondii. The organization has 13052 authors who have published 19291 publications receiving 212123 citations.

Copper Ions Adsorption from Aqueous Medium Using the Biosorbent Sugarcane Bagasse In Natura and Chemically Modified

Abstract: This study evaluated the copper ion adsorption capacity of sugarcane bagasse in natura and chemically modified with citric acid and sodium hydroxide. Adsorption analyses in batch system were carried out in function of contact time with the adsorbent and adsorbate concentration. Flame atomic absorption spectrometry was used to determine the copper concentrations. Adsorption experimental data were fitted to Langmuir and Freundlich linear models, and the maximum adsorption capacity was estimated for copper ions in function of modifications. The chemical modifications were confirmed at 1,730 cm−1 peak in infrared spectra, referring to the carboxylate groups. The required time for the adsorption to reach equilibrium was 24 h and the kinetics follows the behavior described by the pseudo-second order equation. Besides, a significant improvement of the copper adsorption has been observed after the bagasse treatment, where the maximum adsorption capacity was 31.53 mg g−1 for copper using modified bagasse with nitric acid according to Langmuir isotherm linear model. The high uptake of copper ions from aqueous medium verified by chemically modified sugarcane bagasse makes this material an attractive alternative for effluent treatment and avoids environmental contamination.

Effect of Intravenous Fluid Treatment With a Balanced Solution vs 0.9% Saline Solution on Mortality in Critically Ill Patients: The BaSICS Randomized Clinical Trial

Abstract: Importance Intravenous fluids are used for almost all intensive care unit (ICU) patients. Clinical and laboratory studies have questioned whether specific fluid types result in improved outcomes, including mortality and acute kidney injury. Objective To determine the effect of a balanced solution vs saline solution (0.9% sodium chloride) on 90-day survival in critically ill patients. Design, Setting, and Participants Double-blind, factorial, randomized clinical trial conducted at 75 ICUs in Brazil. Patients who were admitted to the ICU with at least 1 risk factor for worse outcomes, who required at least 1 fluid expansion, and who were expected to remain in the ICU for more than 24 hours were randomized between May 29, 2017, and March 2, 2020; follow-up concluded on October 29, 2020. Patients were randomized to 2 different fluid types (a balanced solution vs saline solution reported in this article) and 2 different infusion rates (reported separately). Interventions Patients were randomly assigned 1:1 to receive either a balanced solution (n = 5522) or 0.9% saline solution (n = 5530) for all intravenous fluids. Main Outcomes and Measures The primary outcome was 90-day survival. Results Among 11 052 patients who were randomized, 10 520 (95.2%) were available for the analysis (mean age, 61.1 [SD, 17] years; 44.2% were women). There was no significant interaction between the 2 interventions (fluid type and infusion speed;P = .98). Planned surgical admissions represented 48.4% of all patients. Of all the patients, 60.6% had hypotension or vasopressor use and 44.3% required mechanical ventilation at enrollment. Patients in both groups received a median of 1.5 L of fluid during the first day after enrollment. By day 90, 1381 of 5230 patients (26.4%) assigned to a balanced solution died vs 1439 of 5290 patients (27.2%) assigned to saline solution (adjusted hazard ratio, 0.97 [95% CI, 0.90-1.05];P = .47). There were no unexpected treatment-related severe adverse events in either group. Conclusion and Relevance Among critically ill patients requiring fluid challenges, use of a balanced solution compared with 0.9% saline solution did not significantly reduce 90-day mortality. The findings do not support the use of this balanced solution. Trial Registration ClinicalTrials.gov Identifier:NCT02875873